Bicycle Therapeutics Signs a Collaboration Agreement with Novartis to Develop and Commercialize Multiple Targeted Bicycle Radio-Conjugates Therapies
Shots:
- Bicycle to receive a $50M up front, ~$1.7B in development & commercial-based milestones along with royalties on Bicycle-based therapies commercialized by Novartis. Novartis will lead the further development, manufacture & commercialization of the BRCs & will fund all pre-clinical & clinical development & commercialization activities
- The collaboration enables Bicycle to discover and develop new cutting-edge radiopharmaceutical cancer treatments based on Bicycles to be developed into BRCs using its phage platform
- Bicycle’s BT5528, a BTC targeting EphA2; BT8009, a BTC targeting Nectin-4 & a well-validated tumor Ag; and BT7480, a Bicycle TICA targeting Nectin-4 & agonizing CD137 while BT1718 is being studied in P-I/IIa trial
Ref: bicycle-therapeutics | Image: bicycle-therapeutics
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
